Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QNCX Quince Therapeutics, Inc.

Post-Mkt 02-04 16:28:28 EST

0.1589

+0.0135

+9.28%

盘后0.1654

+0.0065+4.09%

16:28 EST

High0.1615	Low0.1400	Vol4.93M
Open0.1466	D1 Closing0.1454	Amplitude14.79%
Mkt Cap8.85M	Tradable Cap7.87M	Total Shares55.68M
T/O741.01K	T/O Rate9.95%	Tradable Shares49.56M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QNCX","market":"US","secType":"STK","nameCN":"Quince Therapeutics, Inc.","latestPrice":0.1589,"timestamp":1770238800000,"preClose":0.1454,"halted":0,"volume":4929675,"hourTrading":{"tag":"盘后","latestPrice":0.1654,"preClose":0.1589,"latestTime":"16:28 EST","volume":78103,"amount":13231.54169832,"timestamp":1770240503791,"change":0.0065,"changeRate":0.040906,"amplitude":0.119572},"delay":0,"changeRate":0.09284731774415414,"floatShares":49558000,"shares":55681490,"eps":-1.209231,"marketStatus":"Post-Mkt","change":0.0135,"latestTime":"02-04 16:28:28 EST","open":0.14655,"high":0.1615,"low":0.14,"amount":741011.5907310001,"amplitude":0.147868,"askPrice":0.1654,"askSize":3000,"bidPrice":0.1581,"bidSize":20,"shortable":0,"etf":0,"ttmEps":-1.209231,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770253200000},"marketStatusCode":4,"adr":0,"listingDate":1557374400000,"exchange":"NASDAQ","adjPreClose":0.1454,"preHourTrading":{"tag":"盘前","latestPrice":0.1416,"preClose":0.1454,"latestTime":"09:29 EST","volume":180016,"amount":26123.698700160003,"timestamp":1770215356270,"change":-0.0038,"changeRate":-0.026135,"amplitude":0.059835},"postHourTrading":{"tag":"盘后","latestPrice":0.1654,"preClose":0.1589,"latestTime":"16:28 EST","volume":78103,"amount":13231.54169832,"timestamp":1770240503791,"change":0.0065,"changeRate":0.040906,"amplitude":0.119572},"volumeRatio":0.315565,"impliedVol":3.7143,"impliedVolPercentile":0.9482},"requestUrl":"/m/hq/s/QNCX","defaultTab":"news","newsList":[{"id":"2608818550","title":"Five Directors Resign from Quince Therapeutics Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2608818550","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608818550?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:31","pubTimestamp":1770067865,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Inc. announced that Rajiv Patni, Luca Benatti, Margi McLoughlin, Una Ryan, and June Bray have resigned from the company's board of directors, effective January 30, 2026. The company stated that the resignations were not due to any disagreements related to company operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL6yw42B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2607024048","title":"Quince Therapeutics Cut to Hold From Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2607024048","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607024048?lang=en_us&edition=fundamental","pubTime":"2026-01-30 20:53","pubTimestamp":1769777580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QNCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 30, 2026 07:53 ET (12:53 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","QNCX","BK4139","BK4007"],"gpt_icon":0},{"id":"2607105682","title":"Quince Ends Development of Lead Drug Candidate; Shares Slide","url":"https://stock-news.laohu8.com/highlight/detail?id=2607105682","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607105682?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:52","pubTimestamp":1769719920,"startTime":"0","endTime":"0","summary":"Quince Therapeutics will end the development of its lead asset, a treatment for the neurodegenerative disorder ataxia-telangiectasia, after a pivotal Phase 3 trial failed to meet its expected outcomes.The drug candidate, dexamethasone sodium phosphate encapsulated in autologous erythrocytes, or eDSP, did not achieve statistical significance its primary and key secondary endpoints, the biotechnology company said Thursday afternoon.Shares for Quince nosedived to 27 cents a share ahead of the market close. The stock opened at $3.18 Thursday.Quince said cancelling the program would preserve cash and allow the company to explore available alternatives.\"We express our compassion and hope for future therapeutic options to the A-T community,\" Chief Executive Officer and Chief Medical Officer Dirk Thye said. \"We have tremendous gratitude toward the patients, their families, academic investigators and study sites, as well as all Quince employees, who worked so diligently over many years on this ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Quince Ends Development of Lead Drug Candidate; Shares Slide","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2607736055","title":"BUZZ-Quince Therapeutics drops after co's drug fails to meet main goal in late-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2607736055","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607736055?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:46","pubTimestamp":1769719589,"startTime":"0","endTime":"0","summary":"BUZZ-Quince Therapeutics drops after co's drug fails to meet main goal in late-stage trial** Shares of drug developer Quince Therapeutics QNCX.O down shares down 91.7% at 24 cents in afternoon trading","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nL4N3YU2ZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2607055263","title":"Quince down 14% after NEAT study endpoint did not reach statistical significance","url":"https://stock-news.laohu8.com/highlight/detail?id=2607055263","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607055263?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:30","pubTimestamp":1769718620,"startTime":"0","endTime":"0","summary":"Shares of Quince Therapeutics (QNCX) are down 44c, or 14%, to $2.75 after the company reported that the primary endpoint in the Phase 3 NEAT clinic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quince-down-14-after-neat-study-endpoint-did-not-reach-statistical-significance-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quince-down-14-after-neat-study-endpoint-did-not-reach-statistical-significance-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2607987055","title":"Quince Therapeutics trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2607987055","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607987055?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:10","pubTimestamp":1769717438,"startTime":"0","endTime":"0","summary":"15:06 EST Quince Therapeutics (QNCX) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving brea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","QNCX","BK4007","BK4539"],"gpt_icon":0},{"id":"2607055580","title":"Quince Therapeutics Ends Development of eDSP After Phase 3 Trial Misses Key Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2607055580","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607055580?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:10","pubTimestamp":1769717414,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Inc. announced topline results from its pivotal Phase 3 NEAT clinical trial evaluating dexamethasone sodium phosphate encapsulated in autologous erythrocytes  in patients with Ataxia-Telangiectasia (A-T). The trial did not achieve statistical significance for its primary and key secondary endpoints. eDSP was generally well tolerated, with no clinically meaningful safety concerns identified. Quince Therapeutics will cease clinical development of eDSP and intends to preserve cash and explore available options. The company has already presented these results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on Janu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL9lqyVn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2607555990","title":"Quince Therapeutics - to Cease Clinical Development of Edsp","url":"https://stock-news.laohu8.com/highlight/detail?id=2607555990","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607555990?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:10","pubTimestamp":1769717400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nTUABTSWYQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2607205559","title":"Quince Therapeutics - Edsp Well Tolerated With No Safety Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2607205559","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607205559?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:10","pubTimestamp":1769717400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nTUABTSWYQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2607055597","title":"Quince Therapeutics - Primary and Secondary Endpoints Did Not Achieve Statistical Significance","url":"https://stock-news.laohu8.com/highlight/detail?id=2607055597","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607055597?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:10","pubTimestamp":1769717400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nTUABTSWYQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2607005530","title":"Quince Therapeutics Announces Topline Results From Pivotal Phase 3 Neat Clinical Trial of Edsp in Ataxia-Telangiectasia","url":"https://stock-news.laohu8.com/highlight/detail?id=2607005530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607005530?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:10","pubTimestamp":1769717400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nTUABTSWYQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2607553720","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 03:06 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2607553720","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607553720?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:06","pubTimestamp":1769717207,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 03:06 PM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nAQN2LJWN8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2607740671","title":"Quince Therapeutics Reports Long-Term Safety Data for eDSP in Children with Ataxia-Telangiectasia","url":"https://stock-news.laohu8.com/highlight/detail?id=2607740671","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607740671?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:06","pubTimestamp":1769634383,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Inc. announced the presentation of previously published safety data from long-term treatment with encapsulated dexamethasone sodium phosphate  in children with Ataxia-Telangiectasia (A-T) at the British Paediatric Neurology Association 2026 Annual Meeting in Glasgow, Scotland, scheduled for January 28-30, 2026. The analysis evaluated the safety profile of eDSP in children with A-T over a minimum of two years. Findings indicated stable growth and metabolic parameters without evidence of corticosteroid-related toxicities. No concerns related to glucose homeostasis or adrenal suppression were identified, and no confirmed cases of adrenal insufficiency occurred, although routine monitoring is recommended. These results were previously published in the journal Frontiers in Neurology in January 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDLbr7PX6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2605142978","title":"Nasdaq Net Change Percentage Gainers & Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2605142978","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605142978?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:30","pubTimestamp":1768948200,"startTime":"0","endTime":"0","summary":"Leverage 2X Lg IREN Dly     IREG     36.04     6.52     22.08        68,173. Defiance Dly Target 2X Lg   SMCX     13.76     2.47     21.88     6,989,430. GrShr 2x Long SMCI Daily    SMCL      5.46     0.97     21.60    14,233,848. Aimei Health Technology     AFJK     55.23     9.22     20.04       128,874. Airship AI Holdings         AISP      4.32     0.72     20.00     4,387,847. Defiance Lvg Lg+Incm SMCI   SMCC      6.98     0.94     15.53        84,793. Direxion Dly MU Bull 2X      MUU    157.33    21.04     15.44     2,306,047. Defiance Tgt 2X Shrt SMCI   SMCZ     42.75   -12.42    -22.51       638,309. Defiance Tgt 2X Lg DKNG     DKNX      8.37    -1.59    -15.95       265,114. Evolution Metals & Techs    EMAT      8.40    -1.52    -15.32       104,991. Defiance Tgt 2X Lg VST      VSTL     12.81    -2.30    -15.22       984,232. Defiance Tgt 2x Shrt IONQ   IONZ     16.27    -2.66    -14.05     3,905,099. Leverage 2x Lg FIG Dly      FIGG      2.80    -0.42    -13.04     1,155,398.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FIGG","CTMX","AFJK","SMCZ","IONZ","SMCC","VSTL","LU1861215975.USD","ABUS","BK4588","AXTI","QNCX","BK4543","BK4585","BK4170","DKNG","PRLD","SMCL","RKLZ","AISP","EMAT","LU0053671581.USD","LU1861220033.SGD","IREG","SMCX","IBRX","DKNX"],"gpt_icon":1},{"id":"2595075514","title":"Quince Therapeutics Director Luca Benatti Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2595075514","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595075514?lang=en_us&edition=fundamental","pubTime":"2025-12-30 06:36","pubTimestamp":1767047808,"startTime":"0","endTime":"0","summary":"Luca Benatti, Director of Quince Therapeutics Inc., reported a disposal of common shares of Quince Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL7rTHJ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Quince Therapeutics Director Luca Benatti Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2591475266","title":"BRIEF-Quince Marks Final Patient Visit in NEAT Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2591475266","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591475266?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:53","pubTimestamp":1765810389,"startTime":"0","endTime":"0","summary":"BRIEF-Quince Marks Final Patient Visit in NEAT Phase 3 StudyDec 15 (Reuters) - Quince Therapeutics Inc QNCX.O:QUINCE THERAPEUTICS ANNOUNCES LAST PATIENT LAST VISIT IN PHASE 3 NEAT CLINICAL TRIAL IN PA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA9SHPZW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2591961649","title":"Quince Therapeutics Completes Phase 3 NEAT Trial for Ataxia-Telangiectasia Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2591961649","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591961649?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:01","pubTimestamp":1765803698,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Inc. has announced the completion of patient visits in its pivotal Phase 3 NEAT clinical trial evaluating encapsulated dexamethasone sodium phosphate  for the treatment of Ataxia-Telangiectasia (A-T), a rare pediatric neurodegenerative disease with no currently approved treatments. The international, multicenter, randomized, double-blind, placebo-controlled study enrolled 105 participants and was conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. The primary efficacy endpoint is based on changes in the Rescored modified International Cooperative Ataxia Rating Scale  from baseline to the last efficacy visit. Quince Therapeutics expects to report topline results from the trial in the middle of the first quarter of 2026. Results have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL5dGqVG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2591668649","title":"Quince Therapeutics Announces Last Patient Last Visit in Phase 3 Neat Clinical Trial in Patients With Ataxia-Telangiectasia","url":"https://stock-news.laohu8.com/highlight/detail?id=2591668649","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591668649?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:00","pubTimestamp":1765803604,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA9SHPZW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2591649659","title":"Quince Therapeutics - Expects Topline Results in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649659","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649659?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:00","pubTimestamp":1765803604,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA9SHPZW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2590558100","title":"Quince Therapeutics Reports Positive Early Clinical Results for eDSP in Pulmonary and Inflammatory Bowel Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2590558100","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590558100?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400725,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Inc. announced the publication of early-stage clinical studies evaluating its lead asset, eDSP , in pulmonary and inflammatory bowel disorders. The studies, summarized in the journal Frontiers in Drug Delivery, included patients with chronic obstructive pulmonary disease, cystic fibrosis, Crohn's disease, and ulcerative colitis. Results indicated that eDSP was associated with improved clinical outcomes, such as increased FEV1, reduced infections, and corticosteroid withdrawal, without typical corticosteroid-related toxicities. The company stated that topline results from the ongoing Phase 3 NEAT study of eDSP in Ataxia-Telangiectasia are expected in the middle of the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investme","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL8zNvhy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.quincetx.com","stockEarnings":[{"period":"1week","weight":-0.9561},{"period":"1month","weight":-0.9515},{"period":"3month","weight":-0.908},{"period":"6month","weight":-0.9129},{"period":"1year","weight":-0.9091},{"period":"ytd","weight":-0.9566}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.0176},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1535},{"period":"ytd","weight":0.0112}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.091321},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.085092},{"month":3,"riseRate":0.5,"avgChangeRate":0.133761},{"month":4,"riseRate":0.5,"avgChangeRate":-0.084014},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.087389},{"month":6,"riseRate":0.714286,"avgChangeRate":0.184618},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.077216},{"month":8,"riseRate":0.428571,"avgChangeRate":0.032954},{"month":9,"riseRate":0.571429,"avgChangeRate":0.013938},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.049658},{"month":11,"riseRate":0.571429,"avgChangeRate":0.199459},{"month":12,"riseRate":0.285714,"avgChangeRate":0.079276}],"exchange":"NASDAQ","name":"Quince Therapeutics, Inc.","nameEN":"Quince Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Quince Therapeutics, Inc.(QNCX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Quince Therapeutics, Inc.,QNCX,Quince Therapeutics, Inc.股票,Quince Therapeutics, Inc.股票老虎,Quince Therapeutics, Inc.股票老虎国际,Quince Therapeutics, Inc.行情,Quince Therapeutics, Inc.股票行情,Quince Therapeutics, Inc.股价,Quince Therapeutics, Inc.股市,Quince Therapeutics, Inc.股票价格,Quince Therapeutics, Inc.股票交易,Quince Therapeutics, Inc.股票购买,Quince Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Quince Therapeutics, Inc.(QNCX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}